Between pre-conference prep and thousands of abstracts, navigating ASH is tough. Oncology Resource Group is hosting a quick overview to break down what actually matters ahead of New Orleans. If you’re in biopharma commercial, CI, or medical affairs, join us for ONCrg Live: ASH 2026 Preview on Thursday, Dec 10 at 11:00 AM ET. We’ll […]
The ONCrg (Oncology Resource Group) team will be on-site tracking key data readouts, clinical paradigm shifts, and strategic pipeline updates across hematology. Here’s what our analyst team is monitoring based on our conference coverage: 📌 𝐇𝐢𝐠𝐡 𝐈𝐦𝐩𝐚𝐜𝐭 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐅𝐨𝐜𝐮𝐬 𝐀𝐫𝐞𝐚𝐬: • AML/MDS (Targeted agents, including menin-KMT2A/MLL inhibitors) • NHL/CLL (BTK inhibitors and B-cell targeted […]
From practice-changing late-breaking trials to updates across novel mechanisms and combination strategies, the San Antonio Breast Cancer Symposium brings together the global breast cancer community to share the latest clinical advancements. Members of the ONCrg team will be on the ground in San Antonio from December 8–11 analyzing the data, tracking key competitor signals, and […]
This year’s theme, “Crossing the Translational Divide: From Neurons to Novel Therapies,” closely mirrors our commitment to evaluating breakthrough scientific data and translating it into actionable competitive intelligence for oncology innovators. Our Ph.D. analysts look forward to tracking key clinical updates across gliomas, including emerging targeted therapies, cell therapies, and novel treatment combinations to keep […]
ONCrg is attending SITC 2026 in Phoenix, AZ. Our dedicated Ph.D. oncology analysts will be covering key clinical sessions to analyze: 🔹 Late-breaking data on next-generation IO modalities. 🔹 Key competitive shifts impacting the global oncology pipeline. 🔹 Novel multi-MOA approaches: are single molecules engineered to hit multiple targets better than combination regimens pairing two […]
Executive Summary: ONCrg analysts Kristen Cordova and Amber Mineo walk through the highest-impact lung cancer presentations from WCLC 2026 and preview what to watch at ESMO 2026 across small cell and non-small cell lung cancer, covering the context of each readout, how the treatment landscape is expected to shift, and the key questions the analyst team will be chasing.
Which mechanisms are commanding the late-breaker spotlight this year? Our analysts crunched the numbers across all LBAs:
ADCs lead the field — nearly a third of all LBA drugs, spanning NSCLC, breast, ovarian, and beyond.
Our oncology experts will be on the ground, analyzing the latest practice-changing clinical data, trial results, and emerging scientific insights as they unfold across over 20 tumor types.
Join our team as we break down the major readouts shaping thoracic oncology, including: 1L EGFR ex20ins+ NSCLC: First Phase III data for zipalertinib TKI-Naive ROS1+ NSCLC: Potentially registrational data for zidesamtinib 1L HER2m+ NSCLC: First Phase III data readout for T-DXd Relapsed SCLC: First CN Phase III data on two B7-H3 ADCs (tambotatug pelitecan […]